The study is investigating stage-adapted (stage IIA or IIB) de-escalation of standard treatments as part of multimodal treatment with chemotherapy and radiotherapy in seminoma patients.
Aim of the study
The study is investigating whether and how the treatment of men with seminoma (testicular cancer) can be improved. In the study, patients are treated with a combination of chemotherapy and radiotherapy at a reduced intensity. We want to find out whether this form of attenuated therapy is effective compared to standard therapy, whether possible side effects can be avoided and how this affects patients' quality of life.
Who can take part?
Seminoma patients
Procedure
If you take part in the study, you will be assigned to one of two groups. The classification depends on how advanced the cancer is. Patients in group 1 receive chemotherapy with carboplatin on the first day. Radiotherapy begins three weeks later. Patients in group 2 receive chemotherapy with etoposide and cisplatin for the first five days. Radiotherapy begins three weeks later.
Compensation
None
Original study name
Radio-chemotherapy with reduced intensity for stage IIA/B seminoma. A multicenter, open-label Phase II study with two cohorts
BASEC number
2019-00796
Financial support from
Swiss Association for Clinical Cancer Research (SAKK)